Our findings, for the first time, propose that targeting SMAD4 as a pivotal transducer of the TGF-β-signaling pathway may be effective as a supplementary targeted therapy against renal CSCs and may improve the RCC prognosis, particularly the ccRCC subtype. This evidence concerns the gene SMAD4 and nonpapillary renal cell carcinoma.